Heart Failure and Surgical Treatment: When Surgery Can Help a Failing Heart.

Heart failure (HF) affects over 6.5 million Americans and is the leading cause of hospitalization in adults over 65. It occurs when the heart muscle becomes too weak (systolic HF, or HFrEF — heart failure with reduced ejection fraction) or too stiff (diastolic HF, or HFpEF — heart failure with preserved ejection fraction) to pump blood effectively. A normal ejection fraction (EF) is 55-70%; HFrEF is defined as EF ≤40%.

While most heart failure is managed medically — with guideline-directed medical therapy (GDMT) including ACE inhibitors/ARBs/ARNI (sacubitril-valsartan), beta-blockers, mineralocorticoid receptor antagonists (spironolactone/eplerenone), SGLT2 inhibitors (dapagliflozin/empagliflozin), and hydralazine/nitrates — a significant subset of patients have underlying structural heart disease amenable to surgical correction. The critical question is: will fixing the structural problem (coronary disease, valve disease, ventricular geometry) improve the failing heart, or has the heart muscle itself deteriorated beyond recovery?

This guide covers the surgical options for heart failure, from conventional procedures (CABG, valve surgery) to advanced therapies (LVADs, heart transplantation) and emerging approaches (ventricular restoration surgery, cell-based therapies). Understanding when surgery can help — and when it cannot — requires the kind of integrated cardiology-surgery evaluation that the Heart Team approach provides.

Ischemic cardiomyopathy — heart failure caused by coronary artery disease — accounts for approximately 50% of all HFrEF cases. When significant viable (hibernating) myocardium exists behind blocked coronary arteries, revascularization with CABG can restore blood flow, improve contractile function, and reduce heart failure symptoms.

The landmark STICH trial (Surgical Treatment for Ischemic Heart Failure) randomized 1,212 patients with EF ≤35% and coronary artery disease to CABG plus medical therapy vs medical therapy alone. At 5 years, there was no significant difference in all-cause mortality (the primary endpoint). However, the 10-year follow-up (STICHES) showed a significant mortality benefit for CABG: 58.9% vs 66.1% mortality (p=0.02). CABG also reduced cardiovascular mortality, MI, and heart failure hospitalizations.

Key lessons from STICH/STICHES for patients considering CABG for heart failure:

• CABG provides long-term survival benefit, but the benefit takes time to manifest — patients must survive the perioperative period to realize it
• Viability testing (cardiac MRI with gadolinium, PET scan, or dobutamine stress echo) can identify patients most likely to benefit from revascularization, though the STICH viability substudy did not show that viability testing predicted differential CABG benefit
• Patients with the most severe LV dysfunction (EF <20%) and those without significant angina had the least benefit
• The operative mortality for CABG in heart failure patients is higher than for patients with normal EF (3-5% vs 1-2%), reflecting the fragility of the failing heart

Medical therapy must be optimized before and after surgery. GDMT — the "four pillars" of ARNI, beta-blocker, MRA, and SGLT2 inhibitor — should be at target doses or maximum tolerated doses, as these medications have mortality benefits independent of surgical revascularization.

Valvular heart disease and heart failure are intertwined: severe valve disease causes heart failure, and heart failure causes valve disease (functional or secondary regurgitation). Determining whether valve surgery will help a heart failure patient is one of the most challenging clinical decisions in cardiology.

Aortic stenosis with heart failure: Severe aortic stenosis with reduced EF has a dismal prognosis without valve replacement. The question is whether the LV dysfunction is caused by the valve obstruction (afterload mismatch — potentially reversible) or by intrinsic myocardial disease (irreversible). Low-flow, low-gradient aortic stenosis with reduced EF requires dobutamine stress echo to distinguish true severe AS from pseudosevere AS. For patients with true severe AS and heart failure, valve replacement — via TAVR or SAVR — improves survival, even with severely reduced EF.

Mitral regurgitation in heart failure: This is where the distinction between primary and secondary MR is critical. Primary (degenerative) MR causes heart failure by chronic volume overload — surgical repair (preferred) or replacement can reverse the heart failure. Secondary (functional) MR is caused by heart failure — the ventricle dilates, the mitral annulus expands, and the leaflets fail to coapt. Fixing secondary MR does not fix the underlying ventricular disease. The COAPT trial showed that MitraClip improves outcomes in carefully selected secondary MR patients (disproportionate MR relative to LV dysfunction), while MITRA-FR showed no benefit in patients with proportionate MR and larger ventricles.

Tricuspid regurgitation in heart failure: Severe TR is increasingly recognized as an independent driver of right heart failure, organ congestion, and mortality. Surgical repair (annuloplasty) is recommended concomitantly with left-sided valve surgery. Isolated TR surgery is considered for patients with severe TR and symptoms despite diuretic therapy.

When heart failure progresses to end-stage despite optimal medical therapy and conventional surgical options, mechanical circulatory support with a left ventricular assist device (LVAD) becomes a life-saving option. An LVAD is an implantable pump that takes blood from the failing left ventricle and delivers it directly to the ascending aorta, effectively bypassing the weakened heart muscle.

Modern LVADs (HeartMate 3 is the current standard) use a magnetically levitated centrifugal-flow pump with no mechanical bearings, reducing pump thrombosis to under 1%. The device is implanted via sternotomy or less-invasive approaches, with a driveline exiting the skin to connect to external batteries and a controller.

LVAD implantation strategies:

• Bridge to transplant (BTT): LVAD supports the patient while awaiting a donor heart. Stabilizes end-organ function, reverses pulmonary hypertension, and improves surgical candidacy for transplant.
• Destination therapy (DT): For patients who are not transplant candidates (age >70, significant comorbidities, psychosocial factors). The MOMENTUM 3 trial demonstrated 2-year survival of 79% with the HeartMate 3 — a remarkable outcome for patients who would otherwise have 50% 1-year mortality on medical therapy alone.
• Bridge to decision: Temporary support while determining transplant candidacy or myocardial recovery potential.
• Bridge to recovery: In rare cases (particularly acute myocarditis or peripartum cardiomyopathy), ventricular function recovers sufficiently to allow LVAD explantation.

LVAD complications include driveline infection (10-15% per year), stroke (5-10% per year), GI bleeding (15-20% per year, related to acquired von Willebrand syndrome and arteriovenous malformations), and right heart failure post-implant (15-20%). Despite these complications, LVAD therapy dramatically improves survival and quality of life for end-stage heart failure patients.

Heart transplantation remains the gold standard for end-stage heart failure, with median post-transplant survival exceeding 12 years and 1-year survival of approximately 90% at experienced centers. About 3,500-4,000 heart transplants are performed annually in the United States, limited primarily by donor organ availability.

Transplant candidacy is evaluated through a comprehensive multidisciplinary assessment including:

• Cardiopulmonary exercise testing (peak VO2 <12-14 mL/kg/min indicates poor prognosis with medical therapy)
• Right heart catheterization (pulmonary vascular resistance, transpulmonary gradient — elevated PVR may preclude transplant or require LVAD to reverse)
• Psychosocial evaluation (substance abuse history, compliance, social support, cognitive function)
• Age (typically under 70, though some centers accept select patients to 75)
• Comorbidities (renal function, hepatic function, diabetes, obesity, prior malignancy)
• Sensitization panel (HLA antibodies from prior transfusions, pregnancy, or LVAD — high PRA complicates donor matching)

The transplant waiting list is managed by the United Network for Organ Sharing (UNOS), using a 6-status urgency system revised in 2018 to prioritize the sickest patients and reduce geographic disparities. Median wait times vary by blood type, body size, and geography — ranging from months to over a year.

Post-transplant, lifelong immunosuppression is required (typically tacrolimus, mycophenolate, and prednisone), with ongoing surveillance for rejection (endomyocardial biopsy), cardiac allograft vasculopathy (annual coronary angiography or intravascular ultrasound), and malignancy (increased risk from immunosuppression).

For patients who are not transplant candidates, destination therapy LVAD provides a meaningful alternative with improving outcomes as technology advances.

While not "surgery" in the traditional cardiac surgical sense, device-based therapies play a critical role in heart failure management and often intersect with surgical decision-making:

Cardiac Resynchronization Therapy (CRT): For patients with HFrEF (EF ≤35%), NYHA class II-IV symptoms on GDMT, and a wide QRS complex (≥150 ms, especially left bundle branch block), CRT improves symptoms, reduces hospitalizations, and reduces mortality. CRT uses a biventricular pacemaker to coordinate contraction of the left and right ventricles, improving cardiac output by 15-25%. The MADIT-CRT, RAFT, and REVERSE trials established its efficacy. About 30% of patients do not respond to CRT (non-responders), and identifying these patients prospectively remains challenging. His bundle pacing and left bundle branch area pacing are emerging alternatives to traditional CRT with promising early results.

Implantable Cardioverter-Defibrillators (ICDs): For patients with HFrEF (EF ≤35%) despite 3+ months of GDMT, ICDs reduce sudden cardiac death by terminating ventricular tachycardia and ventricular fibrillation. The SCD-HeFT trial showed a 23% relative reduction in all-cause mortality with ICD therapy. Most heart failure patients who receive CRT also receive defibrillator capability (CRT-D).

The relationship between device therapy and surgical planning is important. A patient being considered for CABG or valve surgery with reduced EF may benefit from waiting 3-6 months after surgery to reassess EF before committing to an ICD, since surgical correction of the underlying cause may improve EF above the ICD threshold. This is another area where coordinated Heart Team decision-making — integrating electrophysiology, heart failure cardiology, and cardiac surgery perspectives — is essential.

Several innovative surgical approaches to heart failure are in various stages of development and clinical adoption:

Surgical ventricular restoration (SVR): The Dor procedure or SAVER (surgical anterior ventricular endocardial restoration) aims to restore normal LV geometry by excluding the scarred, akinetic anterior wall from the ventricular cavity after anterior MI. The STICH trial's SVR hypothesis showed no benefit of adding SVR to CABG for patients with anterior akinesia and EF ≤35%. However, proponents argue that proper patient selection (excluding patients with small ventricles) and surgical technique (achieving adequate volume reduction) were not optimally applied in STICH.

Temporary mechanical support: Short-term MCS devices (Impella, TandemHeart, ECMO) provide hemodynamic support for cardiogenic shock and high-risk PCI. Impella devices range from 2.5 L/min (Impella CP) to 5.0 L/min (Impella 5.5 SmartAssist), with placement via the femoral or axillary artery.

Total artificial heart (TAH): The SynCardia TAH is an orthotopic biventricular replacement device used as bridge to transplant for patients with biventricular failure not suitable for LVAD alone. About 50-75 are implanted annually in the US.

Xenotransplantation: The 2022 landmark case at the University of Maryland — transplanting a genetically modified pig heart into a human patient — represented a proof of concept for xenotransplantation. While that patient survived 2 months, the field is advancing rapidly with gene-edited pigs designed to reduce immunologic barriers. If successful, xenotransplantation could eliminate the donor organ shortage.

Cell-based and gene therapies: Multiple clinical trials are evaluating stem cell injections (cardiosphere-derived cells, mesenchymal stem cells) and gene therapy (calcium-handling genes, angiogenic factors) for heart failure. Results have been mixed, with the DREAM-HF trial of mesenchymal precursor cells showing reduction in cardiac events but not the primary endpoint. This remains investigational.

Heart failure surgery is among the highest-stakes clinical decisions, and a second opinion is strongly recommended in these scenarios:

• You have been told you need CABG but have very low EF (≤25%): The risk-benefit calculation for CABG in severely reduced EF is nuanced. Viability assessment, coronary anatomy, surgical risk scoring, and the quality of medical therapy optimization all factor into the decision. A second opinion can confirm whether the potential benefit justifies the elevated surgical risk.
• You have been diagnosed with severe MR and heart failure: Determining whether the MR is the cause of the heart failure (fixable) or the result of it (less fixable by surgery alone) requires expert echocardiographic interpretation and clinical judgment. The implications for treatment strategy are profound.
• You have been told you need an LVAD: LVAD implantation is a life-altering decision with significant long-term implications for lifestyle, complications, and caregiver burden. Have all conventional surgical options (CABG, valve surgery, CRT) been fully explored? Is transplant listing appropriate? These questions merit a second perspective from a fellowship-trained heart failure team.
• You have been told you are too sick for surgery: "Inoperable" at one center may not be inoperable at another. Advanced surgical centers with ECMO, LVAD, and transplant capability may accept patients turned down by community programs. A second opinion from a tertiary center can clarify true surgical candidacy.
• Your EF has not improved despite medical therapy: Are you on maximally tolerated GDMT? Are all four pillars (ARNI, beta-blocker, MRA, SGLT2i) at target doses? Has CRT been considered? Sometimes optimization of medical therapy alone can improve EF and symptoms significantly. A heart failure specialist can review your medication regimen comprehensively.

WhiteGloveMD connects patients with fellowship-trained heart failure cardiologists and cardiac surgeons who independently evaluate your case. Our AI-augmented analysis (Clintelligence) identifies gaps in your workup and treatment optimization. Request your review or view pricing.